Ascendis Pharma Valuation Multiples

Ascendis Pharma Overview

About Ascendis Pharma

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.

Founded

2006

HQ

Employees

1.2K

Website

ascendispharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $1B

EBITDA: $66M

EV

$15B

Valuation Multiples

Multiples.vc

Start free trial

Ascendis Pharma Financials

Ascendis Pharma reported last 12-month revenue of $1B and EBITDA of $66M.

In the same LTM period, Ascendis Pharma generated $941M in gross profit, $66M in EBITDA, and had net loss of ($98M).

Ascendis Pharma P&L

In the most recent fiscal year, Ascendis Pharma reported revenue of $856M and EBITDA of ($121M).

Ascendis Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Ascendis Pharma Stock Performance

Ascendis Pharma has current market cap of $15B, and enterprise value of $15B.

Ascendis Pharma's stock price is $244.48.

Ascendis Pharma Valuation Multiples

Ascendis Pharma trades at 14.1x EV/Revenue multiple, and 231.8x EV/EBITDA.

Ascendis Pharma Financial Valuation Multiples

As of April 19, 2026, Ascendis Pharma has market cap of $15B and EV of $15B.

Equity research analysts estimate Ascendis Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Ascendis Pharma has a P/E ratio of (152.5x).

Ascendis Pharma Margins & Growth Rates

Ascendis Pharma's revenue in the last 12 month grew by 70%.

Ascendis Pharma's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.8M for the same period.

Ascendis Pharma's rule of 40 is 123% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ascendis Pharma's rule of X is 261% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Ascendis Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Ascendis Pharma M&A Activity

Ascendis Pharma acquired XXX companies to date.

Last acquisition by Ascendis Pharma was on XXXXXXXX, XXXXX. Ascendis Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Ascendis Pharma Investment Activity

Ascendis Pharma invested in XXX companies to date.

Ascendis Pharma made its latest investment on XXXXXXXX, XXXXX. Ascendis Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).